A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 103)

November 13, 2026 updated by: Coherus Oncology, Inc.

A Phase 1/2, Multicenter, Open-Label, Multicohort Study Evaluating the Safety and Efficacy of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors

The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

12

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Washington
      • Seattle, Washington, United States, 98109
        • Recruiting
        • Fred Hutchinson Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
  • Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgment.

mCRPC:

  • Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with focal small cell or neuroendocrine (NE) features based on immunohistochemistry (IHC) alone is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is not permitted.
  • Measurable Castration-resistant Prostate Cancer (mCRPC) as defined by PCWG3 criteria. Participant must have mCRPC that is metastatic either to bone, lymph node (LN), or both without clear evidence of either measurable or nonmeasurable metastasis to visceral organs at the time of screening scan.
  • Participants must have been previously treated with at least 1 prior androgen-receptor pathway inhibitor (ARPI) (ie, abiraterone acetate, enzalutamide, apalutamide, darolutamide).
  • Participants must have received at least one prior taxane therapy unless the participant is ineligible or refused. Participants must not have received other prior cytotoxic chemotherapy (ie, cisplatin, carboplatin, etoposide).
  • Prior orchiectomy or medical castration. Participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analog with testosterone ≤50 nanogram per deciliter (ng/dL) prior to the first dose of study drug and must continue this therapy throughout the treatment phase.

Key Exclusion Criteria:

  • History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years.
  • Prior exposure to anti-CCR8 antibody agents.
  • Prior allogeneic hematological stem cell transplantation or organ transplantation.

mCRPC:

  • Any known prior history of brain metastases of prostate cancer (PCa).
  • Treatment with antineoplastic therapy (including but not limited to cytotoxic chemotherapy, biologic agents, and investigational agents) other than ADT or ARPI within 28 days or <5× the elimination half-life (t½), whichever is earlier, before Day 1.
  • Prior exposure to a T cell engager or human kallikrein 2 (KLK2) targeted therapy.
  • Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study.

Additional protocol-defined inclusion and exclusion criteria apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: mCRPC: Tagmokitug + Pasritamig

Specified dose on specified days.

Specified dose on specified days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Up to approximately 2.5 years
Up to approximately 2.5 years
Number of Participants with Dose-limiting Toxicities (DLTs)
Time Frame: Up to 56 Days
Up to 56 Days

Secondary Outcome Measures

Outcome Measure
Time Frame
Objective Response Rate (ORR)
Time Frame: Up to approximately 2.5 years
Up to approximately 2.5 years
Duration of Response (DOR)
Time Frame: Up to approximately 2.5 years
Up to approximately 2.5 years
mCRPC: Prostate Specific Antigen >=50% Response Rate (PSA50) per Prostate Cancer Working Group 3 (PCWG3) Criteria
Time Frame: Up to approximately 2.5 years
Up to approximately 2.5 years
Disease Control Rate (DCR)
Time Frame: Up to approximately 2.5 years
Up to approximately 2.5 years
mCRPC: Radiographic Progression-free Survival (rPFS)
Time Frame: Up to approximately 2.5 years
Up to approximately 2.5 years
Progression-free Survival (rPFS)
Time Frame: Up to approximately 2.5 years
Up to approximately 2.5 years
Maximum Observed Serum Concentration of Tagmokitug (Cmax)
Time Frame: Up to approximately 2.5 years
Up to approximately 2.5 years
Concentration of Tagmokitug Immediately Before the Next Dose (Ctrough)
Time Frame: Up to approximately 2.5 years
Up to approximately 2.5 years
Number of Participants with Anti-drug Antibodies to Tagmokitug
Time Frame: Up to approximately 2.5 years
Up to approximately 2.5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Study Director, Coherus Oncology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

August 1, 2028

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CHS-114-103

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.